Corneal map-dot-fingerprint dystrophy

We’re all in this for good.

By sharing your stories and data, you will:
  • help each other live better and uncover the best ways to manage your health today
  • help researchers shorten the path to new treatments tomorrow

How much good can your data do? A whole lot, as co-founder Jamie Heywood explains in this video.

What is corneal map-dot-fingerprint dystrophy?

Corneal map-dot-fingerprint dystrophy is the most common corneal dystrophy. Most patients are asymptomatic and the condition is found on eye examination. Visual symptoms may include blurred vision, double vision, glare, foreign body sensation, or sensitivity to light.

Common symptoms reported by people with corneal map-dot-fingerprint dystrophy

Common symptoms
How bad it is
What people are taking for it

Reports may be affected by other conditions and/or medication side effects. We ask about general symptoms (anxious mood, depressed mood, fatigue, pain, and stress) regardless of condition.
Last updated:

Treatments taken by people with corneal map-dot-fingerprint dystrophy

Treatment name(s)
Type
How many have tried
Tried for
Treatment name(s)

(Bepreve)
Type
Prescription Drug
How many have tried
1
Treatment name(s)

(Voltaren Gel)
Type
Prescription Drug
How many have tried
1
Tried for
pain (1)
Treatment name(s)

(Muro 128)
Type
Over the Counter Drug
How many have tried
1
Treatment name(s)

(Ultram)
Type
Prescription Drug
How many have tried
1
Tried for
pain (1)

Data from patients with corneal map-dot-fingerprint dystrophy, who reported starting treatments within the last 5 years.
Last updated:

Compare treatments taken by people with corneal map-dot-fingerprint dystrophy

Treatment name(s)
Perceived effectiveness
Side effects
Total evaluations
Tried for
Treatment name(s)

(Bepreve)
Perceived effectiveness
No evaluations
Side effects
No evaluations
Total evaluations
0
Treatment name(s)

(Voltaren Gel)
Perceived effectiveness
No evaluations
Side effects
No evaluations
Total evaluations
0
Tried for
pain (1)
Treatment name(s)

(Muro 128)
Perceived effectiveness
No evaluations
Side effects
No evaluations
Total evaluations
0
Treatment name(s)

(Ultram)
Perceived effectiveness
No evaluations
Side effects
No evaluations
Total evaluations
0
Tried for
pain (1)
  • Major
  • Moderate
  • Slight
  • None
  • Can't tell
  • Severe
  • Moderate
  • Mild
  • None

Data from patients with corneal map-dot-fingerprint dystrophy, who reported starting treatments within the last 5 years.
Last updated:

Who has corneal map-dot-fingerprint dystrophy on PatientsLikeMe?


Age
Age Proportion # of patients
<20 0
20s 0
30s 0
40s 0
50s 0
60s 3
70+ 0
Age at first symptom
Age at first symptom Proportion # of patients
0-19 years 0
20-29 years 0
30-39 years 0
40-49 years 0
50-59 years 1
60-69 years 0
70+ years 0

Distribution of sex

Sex
Sex Proportion # of patients
Male 1
Female 2

Diagnosis status
Diagnosis status Proportion # of patients
Diagnosed 1
Not Diagnosed 0

These charts show data from corneal map-dot-fingerprint dystrophy patients who have completed their condition history
Last updated:
No data

Let’s build this page together! When you share what it’s like to have corneal map-dot-fingerprint dystrophy through your profile, those stories and data appear here too.

Got a question about living with corneal map-dot-fingerprint dystrophy? Members in the forum might have the answers.